Jeito Capital

What is Jeito Capital?

Jeito Capital is a leading international investment company with a focus on advancing patient benefits through the funding and acceleration of cutting-edge medical innovation. They support and collaborate with entrepreneurs by leveraging a multidisciplinary team of experts across the entire value chain of the drug development process, as well as through substantial capital investments to ensure the growth of companies.

Jeito Capital contributes to the creation of leaders in specific therapeutic areas and accelerates the introduction of novel treatments globally, especially in Europe and the United States, for patients who are often in therapeutic deadlocks. Jeito Capital is headquartered in Paris, with a presence in Europe and the United States.

Their portfolio includes significant investments such as a $67.5 million Series B funding for XyloCor Therapeutics to develop new gene therapy for cardiovascular diseases and a $207.5 million oversubscribed Series C funding for Aviceda Therapeutics to advance AVD-104 for the treatment of Geographic Atrophy.

They are recognized not only for their funding capabilities but also for their strategic role in enabling faster patient access to therapies. Entrepreneurs appreciate Jeito’s team for their domain expertise in biotechnology and their practical approach to addressing healthcare system aspects, facilitating the rapid development of treatments.

The firm operates with a vision to establish European champions in the biotech industry and to have a global impact on the healthcare system through practical and patient-centric approaches.